Literature DB >> 10363976

Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1.

D R Gius1, S A Ezhevsky, M Becker-Hapak, H Nagahara, M C Wei, S F Dowdy.   

Abstract

Progression of cells through the G1 phase of the cell cycle requires cyclin D:Cdk4/6 and cyclin E:Cdk2 complexes; however, the duration and ordering of these complexes remain unclear. To address this, we synthesized a peptidyl mimetic of the Cdk4/6 inhibitor, p16INK4a that contained an NH2-terminal TAT protein transduction domain. Transduction of TAT-p16 wild-type peptides into cells resulted in the loss of active, hypophosphorylated pRb and elicited an early G1 cell cycle arrest, provided cyclin E:Cdk2 complexes were inactive. We conclude that cyclin D:Cdk4/6 activity is required for early G1 phase cell cycle progression up to, but not beyond, activation of cyclin E:Cdk2 complexes at the restriction point and is thus nonredundant with cyclin E:Cdk2 in late G1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10363976

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors.

Authors:  V P Torchilin; R Rammohan; V Weissig; T S Levchenko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

2.  SIRT3 deacetylates and increases pyruvate dehydrogenase activity in cancer cells.

Authors:  Ozkan Ozden; Seong-Hoon Park; Brett A Wagner; Ha Yong Song; Yueming Zhu; Athanassios Vassilopoulos; Barbara Jung; Garry R Buettner; David Gius
Journal:  Free Radic Biol Med       Date:  2014-08-22       Impact factor: 7.376

3.  Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization.

Authors:  Andrew G Muntean; Liyan Pang; Mortimer Poncz; Steven F Dowdy; Gerd A Blobel; John D Crispino
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

Review 4.  Designing protein-based biomaterials for medical applications.

Authors:  Jennifer E Gagner; Wookhyun Kim; Elliot L Chaikof
Journal:  Acta Biomater       Date:  2013-10-09       Impact factor: 8.947

5.  Transforming growth factor beta targeted inactivation of cyclin E:cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity.

Authors:  H Nagahara; S A Ezhevsky; A M Vocero-Akbani; P Kaldis; M J Solomon; S F Dowdy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

6.  Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo.

Authors:  S A Ezhevsky; A Ho; M Becker-Hapak; P K Davis; S F Dowdy
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

7.  Commitment point during G0-->G1 that controls entry into the cell cycle.

Authors:  Nicholas C Lea; Stephen J Orr; Kai Stoeber; Gareth H Williams; Eric W-F Lam; Mohammad A A Ibrahim; Ghulam J Mufti; N Shaun B Thomas
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

8.  Pre-Treatment of Pterostilbene Enhances H2O2-induced Cell Apoptosis Through Caspase-dependent Pathway in Human Keratinocyte Cells.

Authors:  Yu-Cheng Chou; Shu-Fen Peng; Yi-Ching Cheng; Po-Yuan Chen; Tzong-DER Way; Ching-Ling Cheng; Yi-Ping Huang; Te-Chun Hsia
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 9.  Metabolic regulation of Sirtuins upon fasting and the implication for cancer.

Authors:  Yueming Zhu; Yufan Yan; David R Gius; Athanassios Vassilopoulos
Journal:  Curr Opin Oncol       Date:  2013-11       Impact factor: 3.645

10.  Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes.

Authors:  Vladimir P Torchilin; Tatyana S Levchenko; Ram Rammohan; Natalia Volodina; Brigitte Papahadjopoulos-Sternberg; Gerard G M D'Souza
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.